Prof Barbara Eichhorst presents data from the randomised phase III GAIA/CLL13 trial during a press conference at the EHA 2022 meeting.
The study evaluated targeted therapy combinations with venetoclax vs chemoimmunotherapy in chronic lymphocytic leukaemia patients.
Watch our interview with Dr Eichhorst here
Read the news story here